Merrimack Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Merrimack Pharmaceuticals, Inc.
Among other Asia deals, Takeda adds to pair of recent gene therapy tie-ups with a CNS-focused cell therapy partnership with Immusoft; earlier it licensed ex-US rights to JCR’s Hunter syndrome drug.
Everest Medicines’ deal with Canadian biotech Providence Therapeutics contains a full transfer of technology which may be appealing to Chinese regulators.
Stock-and-cash deal valued at $229m brings AzurRx rights to niclosamide in additional indications. Boehringer Ingelheim partners with Twist on therapeutic antibody discovery.
Emerging Company Profile: Monument Therapeutics’ novel approach to CNS drug development focuses on repurposing existing drugs with the aid of digital biomarkers.
- Drug Delivery
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Nanotechnology, Chips, etc.
Drug Discovery Tools
- Other Names / Subsidiaries
- Hermes Biosciences, Inc.